(S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(2 H-tetrazol-5-yl)propanoate | 151275-42-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(2 H-tetrazol-5-yl)propanoate
• 英文别名: methyl (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(2H-tetrazol-5-yl)propanoate
• CAS: 151275-42-2
• 化学式: C₁₀H₁₇N₅O₄
• 分子量: 271.276
• InChiKey: KTLWOSGMBUELKO-LURJTMIESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  methyl (S)-2-((t-butoxycarbonyl)amino)-3-cyanopropanoate 在 sodium azide 、 三乙胺盐酸盐 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以44 %的产率得到(S)-methyl 2-((tert-butoxycarbonyl)amino)-3-(2 H-tetrazol-5-yl)propanoate
  参考文献：
  名称：

  [EN] HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H
  [FR] DÉRIVÉS D'HÉTÉROARYL-AMINOPROPANOL EN TANT QU'INHIBITEURS DE LTA4H

  摘要：

  本申请涉及公式（I）的白三烯A4水解酶（LTA4H）抑制剂，用于治疗各种疾病。

  公开号：

  WO2022219546A1

文献信息

• Selective Cysteine Protease Inhibitors and Uses Thereof
  申请人：Ahlfors Jan-Eric

  公开号：US20140038903A1

  公开（公告）日：2014-02-06

  The present invention relates to compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases. Also described are methods where the compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 are used in the prevention and/or treatment of various diseases and conditions in subjects, including cysteine protease-mediated diseases and/or caspase-mediated diseases such as sepsis, myocardial infarction, cancer, tissue atrophy, ischemia, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative diseases such as multiple sclerosis (MS), ALS, Alzheimer's disease, Parkinson's disease, and Huntington's disease).

  本发明涉及公式I、II、IA-VA、IVA1-IVA5、IIIA1-IIIA5化合物及其药物用途。本发明的特定方面涉及使用这些化合物选择性地抑制一个或多个半胱氨酸蛋白酶的用途。还描述了使用公式I、II、IA-VA、IVA1-IVA5、IIIA1-IIIA5化合物在预防和/或治疗受体中的各种疾病和病况，包括半胱氨酸蛋白酶介导的疾病和/或半胱氨酸蛋白酶介导的疾病，如败血症、心肌梗塞、癌症、组织萎缩、缺血、缺血性中风、脊髓损伤（SCI）、创伤性脑损伤（TBI）和神经退行性疾病，如多发性硬化症（MS）、ALS、阿尔茨海默病、帕金森病和亨廷顿病等。
• Selective cysteine protease inhibitors and uses thereof
  申请人：Genesis Technologies Limited

  公开号：US10975119B2

  公开（公告）日：2021-04-13

  The present invention relates to compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases. Also described are methods where the compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 are used in the prevention and/or treatment of various diseases and conditions in subjects, including cysteine protease-mediated diseases and/or caspase-mediated diseases such as sepsis, myocardial infarction, cancer, tissue atrophy, ischemia, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, and Huntington's disease.

  本发明涉及式 I、II、IA-VA、IVA1-IVA5、IIIA1-IIIA5 的化合物及其药物用途。本发明的特定方面涉及这些化合物在选择性抑制一种或多种半胱氨酸蛋白酶方面的用途。还描述了式 I、II、IA-VA、IVA1-IVA5、IIIA1-IIIA5 的化合物用于预防和/或治疗受试者的各种疾病和病症的方法，包括半胱氨酸蛋白酶介导的疾病和/或 Caspase 介导的疾病，如败血症、心肌梗塞、癌症、组织萎缩、缺血、缺血性中风、脊髓损伤 (SCI)、创伤性脑损伤 (TBI) 和神经退行性疾病，如多发性硬化症 (MS)、肌萎缩性脊髓侧索硬化症 (ALS)、阿尔茨海默氏病、帕金森氏病和亨廷顿氏病。
• SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF
  申请人：Genesis Technologies Limited

  公开号：US20180186833A1

  公开（公告）日：2018-07-05

  The present invention relates to compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases. Also described are methods where the compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 are used in the prevention and/or treatment of various diseases and conditions in subjects, including cysteine protease-mediated diseases and/or caspase-mediated diseases such as sepsis, myocardial infarction, cancer, tissue atrophy, ischemia, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative diseases such as multiple sclerosis (MS), ALS, Alzheimer's disease, Parkinson's disease, and Huntington's disease).
• US9944674B2
  申请人：——

  公开号：US9944674B2

  公开（公告）日：2018-04-17